Company Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L3006

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 26/04/2024 BST			5-day change	1st Jan Change
0.6375 ^USD	+1.19%		-10.20%	-87.00%

03-15	Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating	MT
03-14	Quoin Pharmaceuticals Seeks M&A Opportunities	CI

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Companyâs first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.

Number of employees: 4

Managers	Title	Age	Since
Michael Myers CEO	Chief Executive Officer	62	04/03/18
Denise Carter FOU	Founder	55	04/03/18
Gordon Dunn DFI	Director of Finance/CFO	60	31/10/21

Members of the board	Title	Age	Since
Michael Sember BRD	Director/Board Member	-	27/10/21
Dennis Langer BRD	Director/Board Member	73	27/10/21
Joseph Cooper BRD	Director/Board Member	66	27/10/21
Anthony Culverwell BRD	Director/Board Member	68	27/10/21
Michael Myers CEO	Chief Executive Officer	62	04/03/18
Denise Carter FOU	Founder	55	04/03/18
Natalie Leong BRD	Director/Board Member	39	27/10/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,685,970	967,867 ( 26.26 %)	0	26.26 %

Name	Equities	%	Valuation
G1 Execution Services LLC 0.5689 %	20,968	0.5689 %	19 920 $
RhumbLine Advisers LP 0.0288 %	1,063	0.0288 %	1 010 $
LM Advisors LLC 0.000434 %	16	0.000434 %	15 $
Goldman Sachs & Co. LLC (Private Banking) 0.000109 %	4	0.000109 %	4 $
The Huntington National Bank (Columbus, Ohio) 0.000027 %	1	0.000027 %	1 $
Heights Capital Management, Inc. 0.000000 %	0	0.000000 %	- $

Name	Equities	%	Valuation
Michael Myers 0.2539 %	9,358	0.2539 %	8 890 $
Denise Carter 0.2539 %	9,357	0.2539 %	8 889 $
Dennis Langer 0.009495 %	350	0.009495 %	333 $
Anthony Culverwell 0.008600 %	317	0.008600 %	301 $
Michael Sember 0.000000 %	0	0.000000 %	- $
Joseph Cooper 0.000000 %	0	0.000000 %	- $
Gordon Dunn 0.000000 %	0	0.000000 %	- $
Natalie Leong 0.000000 %	0	0.000000 %	- $

Quoin Pharmaceuticals Ltd.

42127 Pleasant Forest Court

20148-7349, Ashburn

http://www.quoinpharma.com

address Quoin Pharmaceuticals, Ltd.(QNRX)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.6375 USD

Average target price

5.8 USD

Spread / Average Target

+809.80%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
QUOIN PHARMACEUTICALS, LTD.	-87.00%	2.35M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research